Baxter International has submitted a BLA to the FDA for the approval of OBI-1, a recombinant antihemophilic porcine sequence factor VIII, in patients with acquired hemophilia A. Phase II/III data supporting the submission were presented at the American Society of Hematology’s (ASH) 55th Annual Meeting in New Orleans, LA. The global, prospective, multi-center, open label clinical trial examined the efficacy and safety of OBI-1 in the treatment of serious bleeds in adults with acquired hemophilia...